Yes, there seems to be a lot of pieces in place that could potentially create a bright future for RGBP. I just wish they would connect the dots, be more consistent and timely in follow ups for things submitted (still no dCellVax IND follow up for data submitted nor any news on Jan filing of HemaX ODD etc.) and create momentum and buzz with the PRs instead of facts without how the facts came about etc.
If news and updates on news were issued on a regular and timely basis it would create greater confidence for investors to see that the company is being transparent and we know the ups and downs.
For example, not commenting at all on the filing for ODD for HemaX 5 months after the fact makes people wonder. Is the company incompetent, was the filing rejected, did the FDA lose the filing, did the filing get lost in the mail, did the FDA want more experiments and data....
I'd rather have bad news or news of the delay and why and the action to resolve than just perturbing silence.
Since RGBP is paying out 10K/month for a company to license or sell something, one thing seems certain: 1. either RGBP is serious about non dilution and has something worth selling or 2. they've given up on being able to locate funds themselves and are desperately in need of funds to stay afloat and so are going outside.
Seems to me that with the promising initial results in the NR2F6 research (something I saw from the early stages as being the main potential for future income), and the fact that if they keep issuing shares, they reduce partnership interest to some extent, that they are willing to sell off other assets they don't have the money to develop in order to get the money or partner to move all aspects of NR2F6 forward, which is fine with me. Just give me the updates and some of the specifics as to how things have come about. Who and where were the activators of NR2F6 discovered, for example?
Other companies give investors a lot more of the plans, timing and progress updates. RGBP now seems in a mode of only good news when they can give it. The rest is mysteriously silent.
